Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Saville

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Sexually Transmitted Diseases|June 14, 2017
Biological and Behavioral Factors Associated With Positive Chlamydia RetestsKirsty S Smith, Rebecca Guy, Jennifer Danielewski, et al.
Journal of Virological Methods|March 7, 2025
Clinical validation of the Roche cobas HPV test on the Roche cobas 6800 system for the purpose of cervical screening and qualification as a second-generation comparator testMarco Ho Ting Keung, Nikita Mehta, Elliott Lynn, et al.
The Lancet. Public Health|December 19, 2017
Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling studyJie-Bin Lew, D James B St John, Xiang-Ming Xu, et al.
Preventive Medicine Reports|September 2, 2024
Correlates of intention-to-attend and confirmed cervical screening attendance during the COVID-19 pandemic in Australia: Findings from Compass-PLUS, a prospective cohort studyLouiza S Velentzis, Sam Egger, Jo Waller, et al.
International Journal of Cancer|July 6, 2017
Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccinationJulia M L Brotherton, Sepehr N Tabrizi, Samuel Phillips, et al.
Tumour Virus Research|February 3, 2023
Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screeningLouiza S Velentzis, David Hawkes, Michael Caruana, et al.
BMC Infectious Diseases|April 25, 2014
Rationale and design of REACT: a randomised controlled trial assessing the effectiveness of home-collection to increase chlamydia retesting and detect repeat positive testsKirsty S Smith, Jane S Hocking, Marcus Chen, et al.
Journal of Primary Health Care|January 21, 2026
'Point-of-Care-Testing is definitely the way to go': primary healthcare professionals in rural Aotearoa New Zealand talk about point-of-care testing for cervical cancer preventionNgaire Kereru Sparkes, Anna Adcock, Tania Slater, et al.
Plos One|March 23, 2023
Te Ara Waiora-Implementing human papillomavirus (HPV) primary testing to prevent cervical cancer in Aotearoa New Zealand: A protocol for a non-inferiority trialMelanie Gibson-Helm, Tania Slater, Evelyn J MacDonald, et al.
BMJ Open|January 5, 2023
Management of Chlamydia Cases in Australia (MoCCA): protocol for a non-randomised implementation and feasibility trialJane L Goller, Jacqueline Coombe, Meredith Temple-Smith, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Sexually Transmitted Diseases|June 14, 2017
Biological and Behavioral Factors Associated With Positive Chlamydia RetestsKirsty S Smith, Rebecca Guy, Jennifer Danielewski, et al.
Journal of Virological Methods|March 7, 2025
Clinical validation of the Roche cobas HPV test on the Roche cobas 6800 system for the purpose of cervical screening and qualification as a second-generation comparator testMarco Ho Ting Keung, Nikita Mehta, Elliott Lynn, et al.
The Lancet. Public Health|December 19, 2017
Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling studyJie-Bin Lew, D James B St John, Xiang-Ming Xu, et al.
Preventive Medicine Reports|September 2, 2024
Correlates of intention-to-attend and confirmed cervical screening attendance during the COVID-19 pandemic in Australia: Findings from Compass-PLUS, a prospective cohort studyLouiza S Velentzis, Sam Egger, Jo Waller, et al.
International Journal of Cancer|July 6, 2017
Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccinationJulia M L Brotherton, Sepehr N Tabrizi, Samuel Phillips, et al.
Tumour Virus Research|February 3, 2023
Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screeningLouiza S Velentzis, David Hawkes, Michael Caruana, et al.
BMC Infectious Diseases|April 25, 2014
Rationale and design of REACT: a randomised controlled trial assessing the effectiveness of home-collection to increase chlamydia retesting and detect repeat positive testsKirsty S Smith, Jane S Hocking, Marcus Chen, et al.
Journal of Primary Health Care|January 21, 2026
'Point-of-Care-Testing is definitely the way to go': primary healthcare professionals in rural Aotearoa New Zealand talk about point-of-care testing for cervical cancer preventionNgaire Kereru Sparkes, Anna Adcock, Tania Slater, et al.
Plos One|March 23, 2023
Te Ara Waiora-Implementing human papillomavirus (HPV) primary testing to prevent cervical cancer in Aotearoa New Zealand: A protocol for a non-inferiority trialMelanie Gibson-Helm, Tania Slater, Evelyn J MacDonald, et al.
BMJ Open|January 5, 2023
Management of Chlamydia Cases in Australia (MoCCA): protocol for a non-randomised implementation and feasibility trialJane L Goller, Jacqueline Coombe, Meredith Temple-Smith, et al.
Pageof 10